AbbVie Inc. (ABBV) had a weak trading session and its shares were last down at $60.89, down -0.22% or -0.36 points. The trading data also revealed that the total net flow stood at $21.1 million as the shares had $84.75 million in upticks but lost $63.66 million in downticks. The up/down ratio was 1.33. This data is particularly important for the traders and speculators alike as it could also be used to gauge the strength of the momentum in the shares. During the past week, the shares have seen a change of 1.48% in the shares.The block trade data suggests an inflow of $30.13 million in upticks and an outflow of $8.78 million in downticks. The up/down ratio for the block stood at 3.43. The net money flow for this transaction was recorded at $21.35.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
AbbVie Inc. has lost 0.8% in the last five trading days and dropped 1.78% in the last 4 weeks. AbbVie Inc. is up 10.26% in the last 3-month period. Year-to-Date the stock performance stands at -1.78%. AbbVie Inc. (NYSE:ABBV) witnessed a decline in the market cap on Wednesday as its shares dropped 0.36% or 0.22 points. After the session commenced at $61.07, the stock reached the higher end at $61.1 while it hit a low of $60.27. With the volume soaring to 5,888,681 shares, the last trade was called at $60.89. The company has a 52-week high of $68.1239. The company has a market cap of $98,952 million and there are 1,625,099,000 shares in outstanding. The 52-week low of the share price is $51.6.
Company has reported several Insider transactions to the SEC, on Dec 2, 2016, William J Chase (EVP, Chief Financial Officer) sold 6,600 shares at 59.19 per share price.On Nov 18, 2016, Thomas A. Hurwich (VP, Controller) sold 3,100 shares at 62.00 per share price.On Sep 9, 2016, Laura J Schumacher (Executive Vice President) sold 50,000 shares at 65.00 per share price.
AbbVie Inc Last issued its quarterly earnings results on Jan 27, 2017. The company reported $1.20 EPS for the quarter. Analyst had a consensus estimate of $1.20. The company had revenue of $6784.00 million for the quarter, compared to analysts expectations of $6902.70 million. The companys revenue was up 6.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.13 EPS.
AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The companys mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the worlds most complex and serious diseases. AbbVie aims to help patients live healthier lives and collaborate on sustainable healthcare solutions.